/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Moderna, Inc. Share Price Today: Live Updates & Key Insights

Moderna, Inc. share price today is $53.62, up -4.61%. The stock opened at $54.75 against the previous close of $55.97, with an intraday high of $55.02 and low of $53.23.

Moderna, Inc. Share Price Chart

style
pb-0

Moderna, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Moderna, Inc. Share Price Performance

$53.62 -0.0461(-4.61%) MRNA at 13 Mar 2026 02:20 PM Biotechnology
Lowest Today 53.23
Highest Today 55.02
Today’s Open 54.75
Prev. Close 55.97
52 Week High 59.55
52 Week Low 22.28
Day’s Range: Low 53.23 High 55.02
52-Week Range: Low 22.28 High 59.55
1 day return -
1 Week return +1.61
1 month return +26.45
3 month return +78.32
6 month return +123.62
1 year return +55.61
3 year return -63.89
5 year return -62.85
10 year return -

Moderna, Inc. Institutional Holdings

Vanguard Group Inc 10.53

BlackRock Inc 7.48

FMR Inc 7.10

Baillie Gifford & Co Limited. 5.21

State Street Corp 4.33

Vanguard Total Stock Mkt Idx Inv 2.80

Morgan Stanley - Brokerage Accounts 2.52

American Funds Growth Fund of Amer A 2.41

Capital Group Growth Fnd of Amer Comp 2.41

Geode Capital Management, LLC 2.34

Vanguard 500 Index Investor 2.24

Amvescap Plc. 2.08

Theleme Partners LLP 2.05

Vanguard Small Cap Index 2.02

Scottish Mortgage Ord 1.99

Two Sigma Advisers, LLC 1.96

Two Sigma Investments LLC 1.86

Vanguard International Growth Inv 1.54

Invesco S&P 500® Equal Weight ETF 1.49

D. E. Shaw & Co LP 1.31

Vanguard Small Cap Value Index Inv 1.29

UBS Group AG 1.22

Fidelity Growth Compy Commingled Pl S 1.19

Flagship Ventures Management, Inc. 1.17

Charles Schwab Investment Management Inc 1.17

iShares Core S&P 500 ETF 1.12

Fidelity 500 Index 1.12

BNP Paribas Arbitrage, SA 1.05

Fidelity Growth Company Fund 1.04

Fidelity OTC 1.03

State Street® SPDR® S&P 500® ETF 1.03

State Street® SPDR® S&P® Biotech ETF 0.84

Alyeska Investment Group, L.P. 0.82

The Goldman Sachs Group Inc 0.81

Banque Pictet & Cie SA 0.79

American Funds IS® Growth 1 0.77

Capital Group Growth Composite 0.77

Fidelity Contrafund 0.74

Northern Trust Corp 0.74

iShares Biotechnology ETF 0.66

Moderna, Inc. Market Status

Strong Buy: 5

Buy: 1

Hold: 17

Sell: 3

Strong Sell: 1

Moderna, Inc. Fundamentals

Market Cap 22104.76 M

PB Ratio 2.5103

PE Ratio 0.0

Enterprise Value 17219.77 M

Total Assets 12338.00 M

Volume 6333177

Moderna, Inc. Company Financials

Annual Revenue FY25:1944000000 1944.0M, FY24:3236000000 3236.0M, FY23:9090000000 9090.0M, FY22:19263000000 19263.0M, FY21:17736000000 17736.0M

Annual Profit FY25:1076000000 1076.0M, FY24:1772000000 1772.0M, FY23:3408000000 3408.0M, FY22:13847000000 13847.0M, FY21:15119000000 15119.0M

Annual Net worth FY25:-2822000000 -2822.0M, FY24:-3561000000 -3561.0M, FY23:-3466000000 -3466.0M, FY22:8362000000 8362.0M, FY21:12202000000 12202.0M

Quarterly Revenue Q4/2025:678000000 678.0M, Q3/2025:1016000000 1016.0M, Q2/2025:142000000 142.0M, Q1/2025:107000000 107.0M, Q4/2024:966000000 966.0M

Quarterly Profit Q4/2025:226000000 226.0M, Q3/2025:8000000 8.0M, Q2/2025:23000000 23.0M, Q1/2025:17000000 17.0M, Q4/2024:227000000 227.0M

Quarterly Net worth Q4/2025:-826000000 -826.0M, Q3/2025:-200000000 -200.0M, Q2/2025:-825000000 -825.0M, Q1/2025:-971000000 -971.0M, Q4/2024:-1120000000 -1120.0M

About Moderna, Inc. & investment objective

Company Information Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 4700

Industry Biotechnology

CEO Mr. Stéphane Bancel M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow